AMENDED AND RESTATED NOTE PURCHASE AGREEMENT Dated as of November 21, 2022 among OPTINOSE US, INC. as the Issuer, OPTINOSE AS, as a Guarantor OPTINOSE, INC., as Parent and a Guarantor The other Guarantors from time to time party hereto, The Purchasers...Note Purchase Agreement • November 21st, 2022 • OptiNose, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED NOTE PURCHASE AGREEMENT is entered into as of November 21, 2022 (the “Effective Date”) among OPTINOSE US, INC., a Delaware corporation (the “Issuer”), OPTINOSE AS, a Norwegian private limited liability company with Norwegian business registration number 982 483 131 (the “Norwegian Guarantor”), OPTINOSE, INC., a Delaware corporation (the “Parent”), the other Guarantors (defined herein) from time to time party hereto, the Purchasers (defined herein) from time to time party hereto and BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales, as Collateral Agent.
